Effect of inhibition of the ROCK isoform on RT2 malignant glioma cells

Anticancer Research

Volumn 30, Issue 9, 2010, Pages 3509-3514

  Inaba, Nobuharu ^a,b   Ishizawa, Sho ^b   Kimura, Masaki ^a   Fujioka, Kouki ^b   Watanabe, Michiko ^b   Shibasaki, Toshiaki ^a   Manome, Yoshinobu ^b  

^a KEIO UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ACNU; Cell cycle; Glioma; ROCK isoforms; shRNA

Indexed keywords

NIMUSTINE; RHO KINASE; RHO KINASE 1; RHO KINASE 2; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ISOENZYME; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CELL CYCLE G0 PHASE; CELL CYCLE G2 PHASE; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME INHIBITION; GENE THERAPY; GENETIC TRANSFECTION; GLIOMA CELL; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; CELL CYCLE; DRUG EFFECTS; GENE SILENCING; GENETICS; GLIOMA; HUMAN; IMMUNOBLOTTING; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; GENE KNOCKDOWN TECHNIQUES; GLIOMA; HUMANS; IMMUNOBLOTTING; ISOENZYMES; NIMUSTINE; RATS; RHO-ASSOCIATED KINASES; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 77958549673     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Giese A and Westphal M: Glioma invasion in the central nervous system. Neurosurgery 39: 235-250, 1996.
2. Manome Y, Kobayashi T, Mori M, Suzuki R, Funamizu N, Akiyama N, Inoue S, Tabata Y and Watanabe M: Local delivery of doxorubicin for malignant glioma by a biodegradable PLGA polymer sheet. Anticancer Res 26: 3317-3326, 2006. (Pubitemid 44701503)
3. Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, Long Z, Chiang Y, McGarrity G J, Muul L M, Katz D, Blaese R M and Oldfield E H: Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3: 1354-1361, 1997.
4. Tawara S and Shimokawa H: Progress of the study of rho-kinase and future perspective of the inhibitor. Yakugaku Zasshi 127: 501-514, 2007.
5. Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, Watanabe N, Saito Y, Kakizuka A, Morii N and Narumiya S: The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 15: 1885-1893, 1996.
6. Shimokawa H and Takeshita A: Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25: 1767-1775, 2005.
7. Takeda K, Ichiki T, Tokunou T, Iino N, Fujii S, Kitabatake A, Shimokawa H and Takeshita A: Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc Biol 21: 868-873, 2001. (Pubitemid 32448782)
8. van Nieuw Amerongen GP, van Delft S, Vermeer MA, Collard JG and van Hinsbergh VW: Activation of RhoA by thrombin in endothelial hyperpermeability: role of Rho kinase and protein tyrosine kinases. Circ Res 87: 335-340, 2000.
9. Martinez MC, Randriamboavonjy V, Ohlmann P, Komas N, Duarte J, Schneider F, Stoclet JC and Andriantsitohaina R: Involvement of protein kinase C, tyrosine kinases, and Rho kinase in Ca(2+) handling of human small arteries. Am J Physiol Heart Circ Physiol 279: H1228-1238, 2000.
10. Yamamoto Y, Ikegaki I, Sasaki Y and Uchida T: The protein kinase inhibitor fasudil protects against ischemic myocardial injury induced by endothelin-1 in the rabbit. J Cardiovasc Pharmacol 35: 203-211, 2000.
11. Salhia B, Rutten F, Nakada M, Beaudry C, Berens M, Kwan A and Rutka JT: Inhibition of Rho-kinase affects astrocytoma morphology, motility, and invasion through activation of Rac1. Cancer Res 65: 8792-8800, 2005.
12. Liu S, Goldstein RH, Scepansky EM and Rosenblatt M: Inhibition of Rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res, 2009.
13. Lane J, Martin TA, Watkins G, Mansel RE and Jiang WG: The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int J Oncol 33: 585-593, 2008.
14. Dong L, Pu PY, Wang H, Wang GX, Kang CS and Jiao DR: Study on the expression of epidermal growth factor receptor and p53 in astrocytic gliomas: evidence for a distinct genetic pathway. Zhonghua Bing Li Xue Za Zhi 35: 232-236, 2006 (in Chinese).
15. Yamaguchi F, Saya H, Bruner JM and Morrison RS: Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci USA 91: 484-488, 1994. (Pubitemid 24041426)
16. Han L, Zhang AL, Xu P, Yue X, Yang Y, Wang GX, Jia ZF, Pu P Y and Kang CS: Combination gene therapy with PTEN and EGFR siRNA suppresses U251 malignant glioma cell growth in vitro and in vivo. Med Oncol, 2009.
17. Endersby R and Baker SJ: PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene 27: 5416-5430, 2008.
18. Deng L, Li G, Li R, Liu Q, He Q and Zhang J: Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo. Cancer Biol Ther 9.
19. Bhadriraju K, Yang M, Alom Ruiz S, Pirone D, Tan J and Chen CS: Activation of ROCK by RhoA is regulated by cell adhesion, shape, and cytoskeletal tension. Exp Cell Res 313: 3616-3623, 2007.
20. Yin J and Yu FS: Rho kinases regulate corneal epithelial wound healing. Am J Physiol Cell Physiol 295: C378-387, 2008.
21. Tian YS, Kim HJ and Kim HM: Rho-associated kinase (ROCK) inhibition reverses low cell activity on hydrophobic surfaces. Biochem Biophys Res Commun 386: 499-503, 2009.
22. Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K and Narumiya S: ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 392: 189-193, 1996. (Pubitemid 26276745)
23. Barker M, Hoshino T, Gurcay O, Wilson CB, Nielsen SL, Downie R and Eliason J: Development of an animal brain tumor model and its response to therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 33: 976-986, 1973.
24. 2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol 94: 299-312, 2009.
25. Parr MJ, Manome Y, Tanaka T, Wen P, Kufe DW, Kaelin WG, Jr. and Fine HA: Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med 3: 1145-1149, 1997.
26. Manome Y, Wen PY, Hershowitz A, Tanaka T, Rollins BJ, Kufe DW and Fine HA: Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors. Cancer Immunol Immunother 41: 227-235, 1995.
27. Oellers P, Schroer U, Senner V, Paulus W and Thanos S: ROCKs are expressed in brain tumors and are required for glioma-cell migration on myelinated axons. Glia 57: 499-509, 2009.
28. Hayashi N, Asano K, Suzuki H, Yamamoto T, Tanigawa N, Egawa S and Manome Y: Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo. Prostate 65: 10-19, 2005.
29. Manome Y, Watanabe M, Abe T, Tomita M, Watanabe S, Yokokawa Y, Takahashi Y, Ishii K, Kimura A, Murakami M, Nagata M, Shibata T, Nakamura M, Tanigawa N and Ohno T: Transduction of thymidine Phosphorylase cDNA facilitates efficacy of cytosine deaminase/5-FC gene therapy for malignant brain tumor. Anticancer Res 21: 2265-2272, 2001.
30. Manome Y, Wen PY, Dong Y, Tanaka T, Mitchell BS, Kufe DW and Fine HA: Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat Med 2: 567-573, 1996.
31. 6-methylguanine-DNA methyltransferase mRNA in brain-tumor model resistant to chloroethyl-nitrosourea. Anticancer Res 22: 2029-2036, 2002.
32. Amarzguioui M, Rossi JJ and Kim D: Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett 579: 5974-5981, 2005. (Pubitemid 41484142)
33. Du J and Hannon GJ: Suppression of p160ROCK bypasses cell cycle arrest after Aurora-A/STK15 depletion. Proc Natl Acad Sci USA 101: 8975-8980, 2004.
34. 1 phase cyclin-dependent kinases. Mol Cell Biol 26: 5203, 2006.
35. Anderson SC and SundarRaj N: Regulation of a Rho-associated kinase expression during the corneal epithelial cell cycle. Invest Ophthalmol Vis Sci 42: 933-940, 2001.
36. Ozawa S, Sugiyama Y, Mitsuhashi Y, Kobayashi T and Inaba M: Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product. Cancer Chemother Pharmacol 21: 185-190, 1988.
37. Manome Y, Watanabe M, Futaki K, Ishiguro H, Iwagami S, Noda K, Dobashi H, Ochiai Y, Ohara Y, Sanuki K, Kunieda T and Ohno T: Development of a syngenic brain-tumor model resistant to chloroethyl-nitrosourea using a methylguanine DNA methyltransferase cDNA. Anticancer Res 19: 5313-5318, 1999.
38. Sun P, Gao J, Liu YL, Wei LW, Wu LP and Liu ZY: RNA interference (RNAi)-mediated vascular endothelial growth factor-C (VEGF-C) reduction interferes with lymphangiogenesis and enhances epirubicin sensitivity of breast cancer cells. Mol Cell Biochem 308: 161-168, 2008.